The data forecasts the top 10 best-selling drugs in 2025 by annual revenue. Following Keytruda, Bristol-Myers Squibb (BMS) and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results